Featured Sponsor

Peter R. Nelson is an associate and senior trial attorney in the firm's Westlake Village office. Mr. Nelson is a highly effective and successful defense attorney. He is certified as a lecturer by the State Bar of California Mandatory Continuing Legal Education Program, is the author of multiple publications in the areas of workers' compensation and claims handling, and is extensively trained with experience in the specialized area of fraud defense. He is a featured lecturer at numerous seminars to employer groups, trade organizations, human resources personnel, and claims examiners. In addition to workers' compensation, Mr. Nelson has considerable experience in state and federal court civil litigation. Because of his background as a former private investigator, he is particularly attuned to correct and cost effective investigative techniques and has overseen numerous complex investigations. Mr. Nelson has also acted as an invited judge at the prestigious National Civil Trial Competition hosted by Loyola Law School.

Sponsors

Our School

Please visit our online school.

The WorkCompAcademy is a full featured online learning experience. Our faculty includes the leading practitioners in the California Workers' Compensation Community. Our online curriculum covers all aspects of Workers' Compensation Claims, from basic concepts to advanced topics of value to experienced practitioners such as senior claims exectives, attorneys, and Qualified Medical Evaluators. Students can access classes any time, from any internet connected computer. Courses can be completed at an individualized pace.

Workers' Compensation Daily News for Sep 28, 2016

New Law Limits Employment Litigation - Law and Forum
Tue, 27 Sep 2016 10:13:55 - Pacific Time
Governor Brown signed SB 1241 by Senator Bob Wieckowski (D-Fremont) which limits employment contract restrictions on choice of law and forum.

As a general matter, arbitrations provide an alternative method of dispute resolution, outside of the courts, wherein a neutral third party, known as the arbitrator, renders a decision after a hearing to which both parties have had an opportunity to be heard.

On March 1, 2016, the Senate Judiciary Committee held an informational hearing on the topic of private or contractual arbitration agreements. In that hearing, many issues facing consumers and employees who are subject to arbitration clauses contained in standardized, take-it-or-leave-it, or "adhesive," contracts were brought to light.

A package of arbitration bills, of which this bill is one, arose out of the hearing, seeking to address various fairness issues surrounding the rules that govern the conduct and operation of arbitrators and arbitrations in this state.

Of particular relevance to this bill are issues of fairness surrounding choice of law and choice of forum clauses as a condition of non-negotiable consumer and employment contracts, and, specifically, the ability of a seller or employer to require a California consumer or employee to litigate or arbitrate their claims arising out of California in another state, or pursuant to another state's laws.

Generally speaking, California law does not currently prohibit companies or employers from requiring consumers or employees to agree to a non-California forum or to apply non-California law to resolve their disputes. As a matter of case law, such clauses are valid so long as the California consumer or employee "will not find their substantial legal rights significantly impaired by their enforcement." (America Online, Inc. v. The Superior Court of Alameda County (2001) 90 Cal.App.4th 1, 21, 23.)

This new law seeks to ensure that California consumers and employees cannot be forced to litigate or arbitrate their California-based claims outside of California, under out-of-state laws, as a condition of a consumer or employment contract.

This new law applies to contracts entered into, modified, or extended on or after January 1, 2017. It prohibits an employer from requiring an employee who primarily resides and works in California, as a condition of employment, to agree to a provision that would require the employee to adjudicate outside of California a claim arising in California or deprive the employee of the substantive protection of California law with respect to a controversy arising in California.

The law also makes any provision of a contract that violates these prohibitions voidable, upon request of the employee, and would require a dispute over a voided provision to be adjudicated in California under California law. The law excepts from these provisions a contract with an employee who was individually represented by legal counsel. These provisions become newly added labor code section 925 on January 1.

SB 1201 may have some effect on the adjudication of workers' compensation claims. Arbitration clauses and choice of law rules have been written into NFL player contracts, and have been used to defend workers' compensation claims by these professional athletes. For example, Bruce Matthews played football in the National Football League from 1983 to 2002. On August 5, 2010, an arbitrator ruled that Bruce Matthews could pursue a workers’ compensation claim in California but that the claim must proceed under Tennessee law, if at all. A federal judge in the United States District Court, Southern District of California upheld the arbitrator in the case of National Football League Players' Association v the NFL.

It is likely that this new law will be tested against the strong federal policy favoring such agreements.
Read More...

Governor Brown Vetoes SCIF Executive Hiring Law
Tue, 27 Sep 2016 10:13:49 - Pacific Time
Governor Brown vetoed SB 1451 by Senator Tony Mendoza (D-Artesia). This proposed law would have allowed the State Compensation Insurance Fund board of directors to appoint additional executive and management positions, not to exceed 1 percent of the number of the Fund's civil service employees; and would have sunset that authority on December 31, 2021.

The State Fund sponsored SB 1451 claiming it would expand its ability to attract and retain staff with industry experience and specific expertise to continue its business transformation and respond effectively to market demands and changes. State Fund said it needs the ability to compete with the private market for such talent to bolster capabilities throughout the organization

The purpose of the bill according to the legislative analysis was to "give the State Fund board the flexibility to create additional exempt management positions, allowing it the ability to avoid hiring costly and ultimately temporary consultants without having to come to the Legislature to approve each new position. Providing the authority to fill these positions with appointed employees will allow the organization to respond more quickly to the market and accelerate progress through a multi-year business transformation that more effectively supports California's workers, economy, and businesses by creating more stability in the marketplace."

SCIF argued that "Because State Fund currently lacks the authority to create additional exempt management positions and to hire employees without seeking specific legislation for each position, it is difficult for the organization to create a meaningful and consistent career path for the recruitment and retention of talent with industry experience and specialized technical skills. Currently, State Fund often fills this gap by hiring temporary contract consultants at costly rates. When consultants leave, knowledge expertise and institutional memory is lost.

There was no opposition to the bill in the legislative record. It was approved by both houses of the California Legislature. However, Governor Brown vetoed the proposed law.

In his veto message he said "This bill grants the State Compensation Insurance Fund Board authority to appoint and set the salary for up to eight additional senior management positions."

"Under limited circumstances it has been necessary for state agencies to have salary setting authority for certain positions. I'm not convinced this authority is justified in this instance." Read More...

WCJ Speaks Out on Independent Contractor Rules
Mon, 26 Sep 2016 12:13:12 - Pacific Time
The thorny issue of what defines an employee became a focus of a session on workers’ compensation at the California Hispanic Chambers of Commerce convention Friday in Riverside according to the report in the Press Enterprise.

The issue matters because there is a high percentage of small businesses owned by Latinos in the state and an increasing number of independent contractors.

The status of drivers for transportation provider Uber and some trucking companies has been questioned.

"I’ve done five or six trials this year alone, all trucking companies with the truck drivers as independent contractors, and in each case they turned out to be employees," said Dora Padilla, workers’ compensation judge at the San Jose Workers’ Compensation Appeals Board and a panelist in the session.

A lot of business owners aren’t sure what their obligations are to their workers, she said.

"I find a lot of problems where employers come in, and I believe them when they say, 'My attorney or my insurance person or my next door neighbor or my tio, they told me I can do this and have this person be an independent contractor and, no, I don’t have workers’ comp insurance.'" And a person has gotten hurt. "It never fails it’s some catastrophic injury."

Employers are required to carry workers’ compensation insurance to pay for treatment for employees who sustain physical or psychological injuries on the job.

According to Padilla’s presentation, a hirer is working with an independent contractor when the hirer:

1) Lacks control over detail.

2) Has no right to terminate the relationship.

3) Makes payments by contract price.

4) Does not furnish tools or materials.

5) Does not have control over working hours.

Calling employees independent contractors can have consequences, said Yvonne E. Lang, a partner with Pearlman, Borska & Wax.

"Payroll fraud " don’t do it! ... And if it is an independent contractor, you’d better have a contract." Read More...

Santa Barbara Cop Pleads Guilty in Fraud Case
Mon, 26 Sep 2016 12:13:06 - Pacific Time
A former Santa Barbara police officer is headed to jail for Felony Workers' Compensation Fraud.

Jacob Finerty, 28, of Hesperia, California, entered an open plea to four counts of fraud on Friday.

Officer Finerty claimed to have injured his back in an off-duty accident while he was employed with the Santa Barbara Police Department. He also claimed that he could not perform his usual and customary employment duties as a police officer due to his back injury.

Sergeant Jill Beecher of the Santa Barbara Police Department investigated Finerty's claims. She discovered that during the same time Finerty claimed he couldn't do his job, he was seen on multiple occasions lifting heavy weights, engaging in strength competitions and competing in MAS Wrestling events. Many of those activities were captured on video and photographs and posted on social media.

Sgt. Beecher sent her findings to Deputy District Attorney Gary Gemberling who filed the four felony counts against Finerty.

Finerty entered the open plea to all charges and there was no plea agreement.

Judge Clifford Anderson sentenced Finerty to 120 days in jail, placed him on five years probation and ordered him to payback $115,669.86 to the City of Santa Barbara.

Santa Barbara County District Attorney Joyce Dudley stated, "The fraud committed by the defendant was paid for by the taxpayers of the City of Santa Barbara, the very same people the defendant was hired to protect. His criminal actions caused a significant breach of the public's trust and resulted in his status changing from Santa Barbara Police Officer to a Felon." Read More...

California Sues Drugmakers for Billion Dollar Price Manipulation
Fri, 23 Sep 2016 07:58:20 - Pacific Time
The California Attorney General Kamala D. Harris announced that California, along with 34 other states and the District of Columbia, has filed a lawsuit against Indivior, a British pharmaceutical company, and MonoSol, an Indiana film technology company, for antitrust violations.

The complaint, filed in U.S. District Court for the Eastern District of Pennsylvania, alleges that Indivior and MonoSol engaged in a multi-pronged "product-hopping" scheme to block competition to Suboxone, an opioid addiction treatment, ultimately generating almost one billion dollars in undeserved profits. In this kind of scheme, pharmaceutical companies try to maintain profits generated via a monopoly by slightly reformulating their product in a way that blocks generic competitors without offering any significant medical or therapeutic advantages to patients.

"When prescription drug companies unlawfully manipulate the marketplace to maximize profits, they put lives at risk and drive up the cost of healthcare for everyone. Indivior and Monosol flagrantly violated the law, deceiving doctors and patients and shutting down generic competition in order to rake in profits," said Attorney General Harris. "These companies must be held accountable for this unlawful scheme that cost the public nearly a billion dollars and hampered fair competition in the marketplace."

Indivior, then known as Reckitt Benckiser, was granted FDA approval in 2002 for Suboxone tablets, along with exclusive rights to sell the drug for seven years based on representations that it was unlikely to recover its investment in the drug. During this time, Indivior generated over a billion dollars in sales of the Suboxone tablets.

When its exclusive rights expired in 2009, the company was faced with potential competition expected to eliminate 80% of its profits from Suboxone tablets within a year. Indivior, with MonoSol’s assistance, thwarted that competition by switching the form of Suboxone from tablet to film. It falsely claimed the tablets presented pediatric safety issues, made unfounded claims to physicians that tablets were dangerous, and raised the price of its tablet while lowering the price of the film. Through these actions, Individior was able to maintain artificially high prices for Suboxone, depriving the state and consumers of the benefits of lower prices that come with competition.

The complaint alleges that the conduct and agreement between Indivior and Monosol constitutes monopolization, conspiracy to monopolize, and illegal restraint of trade in violation of federal antitrust laws as well as of California's Cartwright Act and Unfair Competition Law. The complaint seeks to require Indivior to pay back any profits that resulted from the illegal conduct - disgorgement - and includes injunctive relief to ensure the conduct is not continued or repeated.

Indivior said in a statement that it would continue to "vigorously defend" its position.
Read More...

L.A. Jury Convicts Physician for Illegal Drug Prescritions
Fri, 23 Sep 2016 07:58:11 - Pacific Time
The Los Angeles County District Attorney’s Office announced. that a Rancho Palos Verdes physician charged with illegally prescribing drugs to undercover operatives was convicted,

The downtown Los Angeles jury deliberated about two hours before finding Dr. Richard Seongjun Kim, 44, guilty of 17 felony counts of unlawfully prescribing controlled substances without a legitimate medical need to undercover operatives working with the Drug Enforcement Administration. Kim was a 1998 graduate of the University of Alabama School of Medicine. His prescription rights have been suspended by court order since July 15, 2015.

Deputy District Attorney Emily Street of the Major Narcotics Division, who prosecuted the case, said Kim would ask the operatives to bring in prior medical charts and X-rays to justify the prescribing.

On one occasion, an operative brought in a chest X-ray of a dog, including its tail, that was used to justify his prescriptions, prosecutors said.

Over the course of three months in 2014, Kim wrote prescriptions for Norco, Xanax, Soma and Adderall without ever conducting a physical exam, taking any vital signs or completing any medical charts at his clinic on Western Avenue in Rancho Palos Verdes, prosecutors said.

Defense attorney Steve Meister said he was disappointed by the verdict and planned to argue to keep Kim out of jail. "My client has always been a caring and competent physician," Meister said. "While the jury may have concluded that he unlawfully prescribed, custody in this case would be wholly unreasonable."

The case against the general practitioner was investigated by the Drug Enforcement Administration, whose operatives posed as patients at Kim’s Western Avenue clinic over the course of three months in 2014. Deputy Dist. Atty. Emily Street, the prosecutor who handled the case, said that Kim asked patients to bring in previous charts and X-rays to the sham medical exams. "He wanted a lot of records - not because he was interested in patients’ ailments, but he wanted to cover himself," Street said.

His office had no staff and he typically exchanged text messages with patients to arrange appointments. He didn’t accept insurance - only cash or credit cards, the prosecutor said. "He would open up his office and lock the door behind him, and meet with the patient in his office," Street said.

Without examining patients or writing out medical charts, he issued prescriptions for Norco, Xanax, Adderall and Soma, prosecutors said. During appointments, Kim sat behind a desk and engaged in mostly small talk, Deputy Dist. Atty. John Niedermann said in an earlier interview with The Times.

The undercover appointments were recorded by hidden cameras, and the video footage was shown to jurors. "It was all on video, which was really the crux of the case," Street said. "There was no exam whatsoever - no vitals, very little history, if any, taken. It was not much of anything resembling the practice of medicine."

He faces up to 13 years, four months in local custody when he returns on Sept. 30 for sentencing in Department 71 at the Foltz Criminal Justice Center. He had been free on $100,000 bail during his trial, but was immediately remanded after the verdict was read. Read More...

Congressional Committee Blasts Drugmaker CEO
Thu, 22 Sep 2016 09:41:34 - Pacific Time
Members on both sides of the aisle were not buying Mylan Pharmaceuticals CEO Heather Bresch’s defense during a House Committee on Oversight and Government Reform hearing Wednesday according to the story published in the Daily Caller.

Her company’s move to increase the cost of EpiPens by more than 400 percent since 2007 has raised the ire of the entire country.

"I know there is considerable concern and skepticism about the pricing," she told the panel. "I think many people incorrectly assume we make $600 off each EpiPen. This is simply not true."

Bresch, the daughter of Democratic West Virginia Sen. Joe Manchin, said the company makes roughly $50 off each of the life-saving allergy shots and adamantly denied her mother, Gayle Manchin’s position on the National Association of State Boards of Education was used to boost sales.

Ranking Member Elijah Cumming, a Maryland Democrat, blasted Bresch’s prepared testimony, saying he was "not impressed" and believes it’s wrong to get "filthy rich" by exploiting the company’s monopoly on the market.

"They use the simple, but corrupt business model that other drug companies have repeatedly used: find an older, cheap drug that has virtually no competition, and then raise the price over and over and over again," he said.

The embattled CEO argued she didn’t anticipate the financial burdens patients would face due the the sharp rise in costs, adding the company plans to put out a generic version at half the cost.

"You never anticipated this? You raised the price, what did you think was going to happen?" Questioned Chairman Jason Chaffetz, a Utah Republican.

While Bresch maintained the drug is not as profitable as members might believe, she increased her salary by a whopping 671 percent over the course of eight years - racking in a whopping $18,931,068 in 2015.

"I’m a very conservative pro-business Republican, but I am sickened by what I have heard today," Tennessee Republican Rep. John Duncan said, adding he is disgusted she was profiting "on the backs of sick children."

Democratic Rep. Bonnie Coleman of New Jersey slammed Bresch for flying to the hearing on a private jet and the company’s decision to move its headquarters overseas to lower its tax rates. "This is a sham and a shell, and it’s really sad to hear this," Coleman told the CEO.

The EpiPen, an auto-injector used to reverse life-threatening allergic reactions, is inextricably tied to Bresch, whose ascension at the company tracks with the product’s rapid growth. Bresch first adopted EpiPen in 2007, when Mylan purchased the generic drugs division of Germany’s Merck KGaA for $6.7 billion. It was a milestone for the growing company, and then-CEO Robert Coury appointed Bresch to sort out the integration.

It was unremarkable in business terms: a plastic device that, with the push of a button, injected what Bloomberg has estimated to be about a dollar’s worth of the generic hormone epinephrine to treat deadly anaphylactic shock.

It sold for about $57 back then and made just $200 million a year for Merck KGaA, accounting for less than 5 percent of the company’s generics revenue at the time. The price was increased about 400% to about $600 after the acquisition. Read More...

Big Pharma Growth Slows in Foreign Markets
Thu, 22 Sep 2016 09:41:27 - Pacific Time
Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building.

A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but a report in Reuters Health says that emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter.

Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.

The slowdown in China and other top emerging markets is being driven by a number of factors: government pressure on drug prices, slowing economies and in some cases significant currency devaluations.

But the end result is that prescriptions for Americans will fund an even greater slice of the $1 trillion-a-year pharmaceuticals industry.

Company executives insist markets from China to Colombia to Mexico to Myanmar are an important engine of long-term growth, given rising populations, increasing wealth, and the global march of diabetes, heart disease and cancer.

But the short-term picture is not pretty. Emerging market growth is the slowest since drug companies started breaking out such regional sales numbers about seven years ago, with GSK languishing at the bottom of the class.

GSK's drug sales in China fell 14 percent in the three months to the end of June as the company continued to reshape its business following a damaging corruption scandal in 2013, leaving a question mark over whether it can return to growth this year as hoped.

Others are doing better in China, which is now the world's second biggest drugs market behind the United States, but all are struggling with slowing sales growth, which slipped to its lowest rate since 2008 in July.

"Across the board, we are seeing emerging markets register lower growth in local currency and in many cases there have also been big currency devaluations," said Murray Aitken, IMS Health senior vice president and executive director.

By comparison, the United States offers rich pickings at the moment thanks to hugely profitable new drugs for diseases such as cancer and hepatitis C.

Many companies' sales in developing economies come from so-called branded generics, or off-patent medicines that command a premium to those made by local suppliers because the Western drugmaker's name is a proxy for quality.

That business is now under threat as governments promote cheaper unbranded products as a route to universal healthcare.

One sign of the tougher times is the relative dearth of acquisitions in emerging markets by international players after a slew of multibillion-dollar deals between 2008 and 2011. Read More...

FDA Agents Claim Mismanagement Supports High Drug Prices
Wed, 21 Sep 2016 07:12:32 - Pacific Time
A U.S. congressional committee has launched an examination of the Food and Drug Administration's criminal office, raising questions about the unit’s management and handling of cases involving food, drugs and devices.

According to the story reported by Reuters Health, the House Energy and Commerce Committee told FDA Commissioner Robert Califf it is "examining management concerns" and "possible morale concerns with the field offices" of the Office of Criminal Investigations. The September 20 letter, signed by committee chairman Fred Upton and Tim Murphy, chairman of the Subcommittee on Oversight and Investigations, seeks answers to a detailed list of questions by October 12.

An FDA spokeswoman said the agency received the letter and will respond to the committee directly.

The House questions come two weeks after Reuters reported how some FDA agents complain criminal office managers have forced them to pursue cases involving mislabeled foreign-imported injectable drugs, at the expense of cases with more potential to protect the public health.

Current and former agents complain they have turned into the "Botox Police," spending thousands of hours chasing doctors who purchased authentic versions of Allergan's anti-wrinkle drug that were labeled for use in other countries.

Some agents say their efforts have done little more than protect the pharmaceutical industry's high drug prices in the United States.

Those concerns come as the criminal office has had mixed success in bringing cases. From fiscal year 2008-2015, Reuters found, more than half of all opened OCI cases were closed without action.

The House committee asked Califf to explain the process for how criminal cases get opened, and to provide statistics on OCI's arrests, convictions, case initiations and amount of money recovered.

The House committee letter also questions how the FDA responded to two prior reports, from the Government Accountability Office and the Health and Human Services Office of the Inspector General, that were critical of the criminal office.

The 2012 OIG report cited problems with how the Rockville-based office is run and concluded that field offices "lack the discretion" to open cases to address "food and drug concerns prevalent in their locales."

The report cited a lack of independence within the FDA’s criminal office. OCI is housed within the Office of Regulatory Affairs, which is responsible for compliance inspections and helps determine the criminal office’s budget. The inspector general recommended structural changes to "ensure the independence of investigations."

FDA leadership at that time rejected those suggestions.

The criminal office headquarters controls the opening of investigations. Some agents have questioned the office’s priorities and say they have, on occasion, been told not to open cases involving other federal agencies.

A September 2015 email from Robert West, the recently retired Special Agent in Charge of the Miami field office, is one example. West, in the email, contended agencies including the FBI, the HHS OIG and Homeland Security investigators "were riding our coattails and were not bringing anything to the table." Involving those agencies in an investigation from day one, he wrote, "is unacceptable." Read More...

Final L.A. Health Care Multi-Million Dollar Fraud Defendant Sentenced
Wed, 21 Sep 2016 07:12:21 - Pacific Time
With the final defendant receiving a prison term this week, six defendants who participated in a multi-million dollar health care fraud scheme or helped launder the illicit proceeds have now been sentenced to federal prison.

Edgar Pogosian, also known as "Edgar Hakobyan," 32, of Glendale, was sentenced to 18 months in prison. Pogosian was found guilty earlier this year of conspiring to commit money laundering and one count of money laundering.

"Over the course of nearly seven years, this defendant engaged in a wide-ranging money laundering conspiracy in which he received 150 checks and personally laundered over $700,000 in health care fraud proceeds," said United States Attorney Eileen M. Decker. "All of the defendants in this case played a vital role in a scheme that bilked the taxpayers who finance Medicare and utilized sophisticated money laundering techniques to hide their crimes."

Over the past month, United States District Judge Philip S. Gutierrez sentenced two other defendants involved in the scheme:

Karen "Gary" Sarkissian, 44, also of Glendale was sentenced on September 12 to 57 months in federal prison after the same jury that convicted Pogosian found him guilty of conspiring to commit money laundering, six counts of money laundering and five counts of health care fraud; and

L’Tanya Smith, 58, of Ladera Heights, was sentenced on August 22 to 57 months imprisonment after she pleaded guilty to five counts of health care fraud.

Pogosian and Sarkissian were found guilty in February by a federal jury following a four-week trial before Judge Gutierrez. Smith pleaded guilty on the eve of trial.

Sarkissian operated a clinic on Sunset Boulevard in Echo Park and worked there with Smith, a physician’s assistant. Between July 2009 and March 2010, Smith prescribed or ordered medically unnecessary tests and services, some of which were never provided to the patients. Those prescriptions and orders led to more than $1.2 million in fraudulent claims to Medicare from the Sunset clinic. Other providers that received referrals from the Sunset clinic submitted another $10 million in fraudulent claims to Medicare.

Sarkissian also participated in a scheme that laundered the fraudulent proceeds generated through the Sunset Clinic through five bogus corporations set up by two other men, Khachatour Hakobyan (Pogosian’s uncle) and Aram Aramyan, who were previously convicted and sentenced in this case.

Hakobyan, 48, of Glendale, who prosecutors argued was the overall leader of the scheme, was sentenced in January 2016 to 57 months in prison and was ordered to pay $606,681 in restitution after he pleaded guilty to conspiring to launder health care fraud proceeds through the five sham corporations and underreporting his income from the conspiracy on his federal income tax returns. Aramyan, 60, of Glendale, was sentenced in November 2015 to 51 months in prison on similar charges and was ordered to pay $353,669 in restitution.

Hakobyan and Aramyan deposited millions of dollars in fraudulent proceeds into bank accounts for the five sham companies and then wrote checks from these corporations to themselves and their relatives, including Pogosian, who was found guilty based on evidence that he received more than $700,000 in checks from the sham corporations that he either cashed or deposited in his own bank accounts.

With these most recent sentences, six defendants have now been sentenced in relation to a health care fraud scheme related to multiple medical clinics, a durable medical equipment supplier and an independent diagnostic testing facility.

The sixth defendant, a doctor associated with one of those clinics - Claude R. Cahen, 74, of Santa Monica - pleaded guilty to conspiring to commit health care fraud and was sentenced to 12 months and one day of imprisonment in March 2016.
Read More...

Past Week News Archive


Applicant Attorney Faces State Bar Suspension: Tue, 20 Sep 2016 08:33:17 - Pacific Time: Read More...


United Nations Acts to Combat Antibiotic Overuse: Tue, 20 Sep 2016 08:33:09 - Pacific Time: Read More...


So. Cal. Pain Medicine QME Arrested in Fraud Case: Mon, 19 Sep 2016 10:47:09 - Pacific Time: Read More...


Hospitals Continue Overuse of Antibiotics: Mon, 19 Sep 2016 10:47:04 - Pacific Time: Read More...


WCIRB Study Shows Decline in Drug Spending: Fri, 16 Sep 2016 11:54:42 - Pacific Time: Read More...


Hearing Set on Proposed RTW Supplement Program Rules: Fri, 16 Sep 2016 11:54:35 - Pacific Time: Read More...


Claimant Illegal Drug Use - What Are the Odds?: Thu, 15 Sep 2016 09:32:11 - Pacific Time: Read More...


Workers’ Compensation Enters "Soft Market Phase": Thu, 15 Sep 2016 09:32:04 - Pacific Time: Read More...


Former Assemblyman Thomas Calderon Sentenced in Bribery Case: Wed, 14 Sep 2016 08:41:37 - Pacific Time: Read More...


Workers' Comp "Opt-Out" Movement Faces Legal Setback: Wed, 14 Sep 2016 08:41:30 - Pacific Time: Read More...